Welcome to issue #172 FutureFemHealth, (w/c 16 November 2026) - your weekly briefing on the global women’s health market.
This week I’m writing to you from a rather chilly Helsinki! ❄️ I’m here with the Eir Accelerator, where I’ve been running a workshop with founders on how to develop their startup stories and secure media coverage. It’s been lovely to spend time with so many founders working on different areas of women’s health (they are all AMAZING).
Now, onto this week’s news!
🌟 In this week’s briefing:
💍 Natural Cycles enters the smart ring market - and co-founder Dr Elina Berglund Scherwitzl tells FutureFemHealth why.
💰 A$604m for Mayne Pharma as Gedeon Richter expands its US women’s health business.
🏥 Maven opens its virtual clinic to 475+ US insurance plans, expanding access beyond employer-sponsored benefits.
📋 UK regulator launches a four-year women’s health programme to tackle gaps in evidence for medicines and medical devices.
Get in touch to share your news with our 10,000 readers: anna@futurefemhealth.com
👀 Catch up on….

Missed some of our recent analysis? Here are three pieces worth catching up on:
Explore our growing archive of market maps, investment intelligence and industry analysis.
💰 Capital flows
📌 AUSTRALIA: Gedeon Richter agrees to acquire Mayne Pharma for A$604m. Mayne Pharma’s shares jumped 86% following this announcement, with the deal set to give Hungarian drugmaker Gedeon Richter a much bigger presence in the US women’s health market, including products such as the contraceptive Nextstellis. You might remember that Mayne was due to be acquired by Cosette Pharmaceuticals last year, but that deal was blocked by the Australian government over concerns about its local manufacturing operations. This new acquisition is expected to complete in March 2027, subject to approvals. (Continue reading: Reuters)
📌 US: Serena Williams and Beth Ferreira launch Starfire Ventures, targeting a $200m fund. After backing more than 100 startups through Serena Ventures, Williams is launching a new investment firm with longtime partner Beth Ferreira. Starfire plans to invest $1m–$10m in early-stage AI and technology companies, including health and wellness. Women’s health is one area to watch: Williams previously backed Midi Health and Teal Health, and says she wants to continue supporting founders addressing gaps in women’s healthcare. (Continue reading: Forbes)
📌 UK: Calla Lily Clinical Care wins £700k Innovate UK grant for vaginal microbiome health. Calla Lily has become really good at securing competitive grant funding to develop its Callavid vaginal drug-delivery platform. This latest award, its third from Innovate UK, supports a £1m project exploring how Callavid could deliver beneficial bacteria to restore vaginal microbiome health and potentially reduce repeated antibiotic use. It’s the third application of the technology to attract competitive funding, alongside progesterone delivery for fertility and pregnancy support and targeted antibiotics. (Continue reading: News-Medical)
🌟 Industry moves and strategic shifts
📌 UK: Natural Cycles launches its first smart ring for digital contraception. After years of partnering with wearable companies including Oura, Natural Cycles is now adding its own smart ring to the mix! Around 80% of its active users already measure their temperature using wearables, and the NC° Ring gives them another option. Ahead of the launch, I spoke to co-founder Elina Berglund about why the company decided to develop its own ring, and what it means for accessibility, reproductive data privacy and future research, alongside its existing partnerships. (Continue reading: FutureFemHealth)
📌 US: Maven Clinic expands insurance coverage to more than 475 health plans. Earlier this year, Maven launched its direct-to-consumer clinic, allowing women to pay for care themselves rather than relying on their employer to offer it as a benefit. Now it’s taking another step, making its services available through more than 475 US health insurance plans, covering around 80% of privately insured Americans. Starting with hormone care, women can access Maven through their existing insurance (known as being in-network), even if their employer doesn’t offer Maven. And the consumer business is already growing quickly, with subscriptions up an average of 55% a month and around a third of subscribers having previously encountered the brand. (Continue reading: Fierce Healthcare)
📌 US: LERA Health launches AI-powered women’s health platform nationwide. What happens after women receive their test results? LERA combines at-home testing for hormones, gut health, metabolism and stress with a 24/7 AI health coach and access to clinicians when needed. Built on more than 20,000 patient journeys, the platform aims to provide personalised support between appointments. It costs $549 for the initial assessment, followed by $29 a month, and is also available to employers and digital health platforms. (Continue reading: LERA Health)
🩸 Research and women’s health news
📌 UK: Women with autoimmune diseases more likely to have symptoms dismissed as psychological, study finds. Women already account for around 80% of people living with autoimmune diseases, but recent research highlights another challenge: actually getting diagnosed. In a study of more than 6,600 patients, 43% of women reported having their symptoms wrongly attributed to psychiatric causes, compared with 33% of men. Women also reported longer diagnostic delays and more medical appointments before receiving a diagnosis. (Continue reading: NBC News)
📄 Policy watch: risks and opportunities
📌 UK: MHRA launches 2026–2030 Women’s Health Programme. Pregnant women were included in just 1.1% of UK clinical trial applications reviewed by the MHRA, and breastfeeding women in only 0.6%. Now the UK’s medicines and medical devices regulator has launched a four-year programme to tackle gaps in evidence about how treatments and technologies work for women. The programme will focus on improving research, regulatory decisions and access to safe, effective medicines and devices throughout women’s lives. (Continue reading: MHRA)
📆 Save the date
FRANCE: Women’s Health Europe Forum. Paris. November 27. 👉 Register here
That’s all for this week. If you found this briefing useful, please forward it to someone working in women’s health!
Anna
This newsletter is for informational purposes only and should not be considered medical or financial advice.





